The hospital pharmaceuticals market comprises pharmaceutical drugs that are administered to patients admitted in hospitals for treatment. These include generic as well as branded drugs used for various therapeutic applications such as antibiotics, analgesics, respiratory drugs, anaesthetics, and vaccines among others. Rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases and respiratory disorders has significantly increased demand for effective pharmaceutical treatments in hospitals. Furthermore, growing healthcare expenditure across both developed and developing countries is another key factor boosting market growth.
The Global Hospital Pharmaceuticals Market is estimated to be valued at Us$ 322.91 Mn in 2024 and is expected to exhibit a CAGR Of 5.8% over the forecast period 2024 To 2030.
Key Takeaways
Key players operating in the Hospital Pharmaceuticals Market are Iofina Chemical, Inc., IOCHEM Corporation, ISR Holding, Qingdao Bright Moon Seaweed Group Co. Ltd., and Algorta Norte S.A. These players are focused on expanding their production capacities and geographical reach through mergers & acquisitions and collaborations with regional hospitals.
The rising geriatric population suffering from various chronic diseases creates significant opportunities for players to introduce advanced drugs with greater efficacy. Moreover, improving healthcare infrastructure in developing nations is increasing the number of hospitals, which will drive demand for pharmaceutical products over the coming years.
Many leading players have been making efforts to strengthen their global presence through partnerships with major hospitals across key regions such as North America, Europe, Asia Pacific and Latin America. This allows them to serve wider patient bases and benefit from growth opportunities in emerging markets.
Market drivers: Rising healthcare expenditure worldwide is a major factor driving growth of the global hospital pharmaceuticals market. Growing investments by governments in healthcare systems have increased funding for hospitals, thereby augmenting demand for various drugs. Furthermore, increasing incidence of chronic diseases necessitates continuous medical treatments and pharmaceutical needs in hospitals.
Market restraints: However, stringent regulations associated with clinical trials and product approval processes continue to hamper entry of newer players in the market. Moreover, high costs associated with drug development and manufacturing pose challenges, particularly for smaller companies with limited financial capabilities. Patent expirations of blockbuster drugs also negatively impact revenues of manufacturers.
Segment Analysis
The hospital pharmaceuticals market is segmented by drug class into antibiotics, pain medication, anti-cancer drugs, cardiovascular drugs, central nervous system drugs and others. The antibiotics segment dominates the market owing to the high prevalence of hospital-acquired infections and rising antibiotic resistance. Antibiotics are widely prescribed therapeutic drugs used for the treatment of bacterial infections in hospitals. The anti-cancer drugs segment is expected to grow at a significant rate during the forecast period due to the increasing burden of cancer globally.
Global Analysis
North America dominates the global hospital pharmaceuticals market and is expected to continue its dominance during the forecast period. This is attributed to the growing elderly population, increasing prevalence of chronic diseases, advanced healthcare infrastructure, presence of key players and growing healthcare expenditure in the region. The market in Asia Pacific is expected to grow at the highest CAGR during the forecast period due to rising medical tourism, growing focus of major vendors on emerging Asian countries and improving healthcare facilities in countries such as China and India.
Get more insights on – Hospital Pharmaceuticals Market
